Head, Global Regulatory Affairs
Kevin Chapman brings over 25 years of experience as a regulatory professional to his current role at HOST Therabiomics. Prior to joining HOST in October 2016, Kevin held positions at GlaxoSmithKline, Amgen, Covance, Shire, Barrier Therapeutics, Wyeth, Pfizer and BTG. His responsibilities included management of complex projects and the global regulatory teams involved in product development that covered different therapeutic areas such as CNS, haematology/oncology, inflammation and transplant therapies, anti-infectives/anti-virals, metabolic disorders, cardiovascular disease, respiratory disease, gastro-intestinal disorders, and dermatological conditions.
Kevin’s biopharmaceutical development experience covers small molecule and biotechnology products providing strategic input from the early development phase, regulatory review, through to post-licensing activities.